In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full trial results and Research Summary:

CELEBRATE results presented at #AHA25

Nueva forma de leer un electrocardiograma (EKG): Probabilidad de FEVI baja Probabilidad de amiloidosis Probabilidad de estenosis aórtica Probabilidad de FA Gap de la edad (asociada a aumento de mortalidad total y cardiovascular) Y entre muchos otros (riesgo de muerte súbita,

#OPTION main results at #AHA24

Both #OCEAN and #OPTION show strong evidence supporting the role of #afib #ablation in lowering the risk of stroke in #afib! Agree with “most important finding” statement by @kaulcsmc ! @atulverma_md @omwazni @drjohnm @DrRoderickTung @PrashSanders

3/ Lower event rates than expected and optimistic delta render the trial results INCONCLUSIVE! Most important finding: Stroke rate is very low post successful a fib ablation in patients with CHA2DS2-VASc score: 2.2 and no other high-risk factors for stroke.

🗞️ Finerenone in patients with severe heart failure: The #FINEARTS_HF trial @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd https://t.co/ZiPZXesoZD

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

🔴2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology @JACCJournals #Cardiology #CardioEd #FOAMed #AHA2025

#AHA25 takeaways:

POLY-HF trial: Polypill containing metoprolol, spironolactone, and empagliflozin improved EF, QoL, and adherence, and reduced HF hospitalizations at 6 months in HFrEF patients compared to usual care. #AHA25 View the slides here: https://t.co/98PJIQpLRQ

META-AF Trial – Metformin Reduces Arrhythmia Recurrence After AF Ablation in Overweight, Non-diabetic Patients Written by @adam_dr_! ! Summary, analysis and more #AHA2025 coverage below! https://t.co/E6Ut38luYo @CMichaelGibson @ceciliabahit

META-AF trial: In non-diabetic, overweight patients with AF, adjunctive metformin after catheter ablation lowered the risk of recurrent atrial arrhythmias at 1 year compared to standard-of-care. #AHA25 View the slides here: https://t.co/hv5a1sWZ4p

DAPT-MVD results presented at #AHA25

🚨 Breaking from #AHA25 👉 The phase 3 CORALreef HeFH trial brings a major step forward: the first oral PCSK9 inhibitor, enlicitide, cuts LDL-C by ≈60% vs placebo in adults with heterozygous familial hypercholesterolemia already on maximally tolerated statins. 🔹 LDL-C ↓58%

OCEAN trial: For AF patients with ≥1 risk factor post-catheter ablation, low-dose rivaroxaban showed similar rates of stroke/systemic embolism and major bleeding at 3 years compared to aspirin. #AHA25 View the slides here: https://t.co/FMhUbroiyp

Ok you all, here is my take of the CLOSURE AF trial. On @theheartorg https://t.co/WppsVncNfi Teaser: this may herald cardiology's biggest medical reversal. Nonindustry funded, non-biased trial. LAAC clearly inferior to best medical therapy (usually DOAC, but 10% no AC.) #AHA25

Enhorabuena a la Dr T Gil-Jiménez por su excelente Tesis Doctoral, fruto de su esfuerzo y del trabajo multidisciplinar entre Neurología y las Unidades de Imagen y Cardiología Intervencionista de ⁦@cardioclinicoGr⁩ ⁦@clinicogranada⁩ ⁦@CanalUGR⁩ ⁦@saludand⁩

⚠️Escenarios clínicos donde los ACOD no deben indicarse. ✍️🏻🚫💊 🔶️Los ACOD (apixabán, rivaroxabán, dabigatrán y edoxabán) han reemplazado en gran medida a los AVK (warfarina, acenocumarol) para la FA y la TVP/TEP, gracias a su eficacia similar y menor riesgo de sangrado

🚨 Major observational study for #T2D management A systematic review of 1.1M+ patients Combining SGLT2 inhibitors + GLP-1 RAs may cut risk of death, heart failure & kidney events more than either drug alone 💊💉 📉 MACE ↓ 44% ⚰️ CV death ↓ 74% 🏥 HF hospitalisation ↓ 33%